Limits...
PIN1 promoter polymorphism (-842 G>C) contributes to a decreased risk of cancer: Evidence from meta-analysis.

Tao LJ, Chen YS, Yao L, Zou B, Tao LS, Kong J, Liu YQ, Cao Q, Yin CJ - Oncol Lett (2014)

Bottom Line: However, the available results are inconclusive.Overall, the results of the present study demonstrated that individuals carrying the variant C allele (G/C and C/C) were associated with a significantly decreased cancer risk (OR, 0.75; 95% CI, 0.62-0.90 for GC vs.GG; OR, 0.75; 95% CI, 0.64-0.88 for GC/CC vs.

View Article: PubMed Central - PubMed

Affiliation: Department of Urology and Institute of Prostatic Diseases, The Affiliated Wuhu No. 2 People's Hospital of Wannan Medical College, Wuhu, Anhui 241000, P.R. China.

ABSTRACT
Peptidyl-prolylcis-trans isomerase NIMA-interacting 1 (encoded by the PIN1 gene) regulates the conformation of proline-directed phosphorylation sites and is important in the etiology of cancer. Since the identification of a functional polymorphism of PIN1, (-842 G>C; rs2233678), in the PIN1 promoter region, numerous studies have evaluated the association between the PIN1 promoter polymorphism (-842 G>C) and cancer risk. However, the available results are inconclusive. To derive a more precise estimation, a meta-analysis of seven previous case-control studies was performed, which included 4,524 cases exhibiting different tumor types and 4,561 control subjects. The published literature was retrieved from PubMed and EMBASE. Crude odds ratios (ORs) with 95% confidence intervals (CIs) were calculated to evaluate the strength of the association. Overall, the results of the present study demonstrated that individuals carrying the variant C allele (G/C and C/C) were associated with a significantly decreased cancer risk (OR, 0.75; 95% CI, 0.62-0.90 for GC vs. GG; OR, 0.75; 95% CI, 0.64-0.88 for GC/CC vs. GG). In further stratified analyses, a decreased cancer risk was observed in the following subgroups: Breast and lung cancer patients, Asian individuals, and in studies with a sample size >500. The results indicated that the PIN1 promoter polymorphism (-842 G>C; rs2233678) contributes to a decreased risk of cancer via attenuating the transcriptional activity.

No MeSH data available.


Related in: MedlinePlus

Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 C allele frequency between the control subjects stratified by ethnicity.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4114709&req=5

f1-ol-08-03-1360: Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 C allele frequency between the control subjects stratified by ethnicity.

Mentions: A variation in the C allele frequency was identified across the different ethnicities. The mean C allele frequencies in the European and Asian populations were 12.8 and 13.5%, respectively (Fig. 1). As shown in Table II, the variant genotypes were associated with a significantly decreased cancer risk in the dominant genetic model (OR, 0.75; 95% CI, 0.64–0.88; Pheterogeneity =0.046; Fig. 2A). In addition, the variant GC heterozygote was associated with a decreased cancer risk when compared with the wild-type homozygote GG (OR, 0.75; 95% CI, 0.62–0.90; Pheterogeneiy =0.008; Fig. 2B). Furthermore, in the stratified analysis, significantly decreased risks of breast cancer (OR, 0.72; 95% CI, 0.57–0.90; Pheterogeneity =0.408 for GC vs. GG; OR, 0.71; 95% CI, 0.56–0.88; Pheterogeneity =0.493 for GC/CC vs. GG genotype) and lung cancer (OR, 0.64; 95% CI, 0.52–0.79; Pheterogeneity =0.814 for GC vs. GG; OR, 0.65; 95% CI, 0.53–0.79, Pheterogeneity =0.762 for GC/CC vs. GG genotype) were identified. In the subgroup analysis of ethnicity, a significantly decreased risk of cancer was identified among Asians for the GC vs. GG genotype (OR, 0.66; 95% CI, 0.57–0.76; Pheterogeneity =0.564) and the GC/CC vs. GG genotype (OR, 0.67; 95% CI, 0.58–0.77; Pheterogeneity =0.777). According to the sample size, a markedly decreased risk was identified in the subgroup with a sample size >500 (OR, 0.68; 95% CI, 0.59–0.78; Pheterogeneity =0.786 for GC vs. GG; OR, 0.68; 95% CI, 0.59–0.78; Pheterogeneity =0.738 for the GC/CC vs. GG genotype).


PIN1 promoter polymorphism (-842 G>C) contributes to a decreased risk of cancer: Evidence from meta-analysis.

Tao LJ, Chen YS, Yao L, Zou B, Tao LS, Kong J, Liu YQ, Cao Q, Yin CJ - Oncol Lett (2014)

Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 C allele frequency between the control subjects stratified by ethnicity.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4114709&req=5

f1-ol-08-03-1360: Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 C allele frequency between the control subjects stratified by ethnicity.
Mentions: A variation in the C allele frequency was identified across the different ethnicities. The mean C allele frequencies in the European and Asian populations were 12.8 and 13.5%, respectively (Fig. 1). As shown in Table II, the variant genotypes were associated with a significantly decreased cancer risk in the dominant genetic model (OR, 0.75; 95% CI, 0.64–0.88; Pheterogeneity =0.046; Fig. 2A). In addition, the variant GC heterozygote was associated with a decreased cancer risk when compared with the wild-type homozygote GG (OR, 0.75; 95% CI, 0.62–0.90; Pheterogeneiy =0.008; Fig. 2B). Furthermore, in the stratified analysis, significantly decreased risks of breast cancer (OR, 0.72; 95% CI, 0.57–0.90; Pheterogeneity =0.408 for GC vs. GG; OR, 0.71; 95% CI, 0.56–0.88; Pheterogeneity =0.493 for GC/CC vs. GG genotype) and lung cancer (OR, 0.64; 95% CI, 0.52–0.79; Pheterogeneity =0.814 for GC vs. GG; OR, 0.65; 95% CI, 0.53–0.79, Pheterogeneity =0.762 for GC/CC vs. GG genotype) were identified. In the subgroup analysis of ethnicity, a significantly decreased risk of cancer was identified among Asians for the GC vs. GG genotype (OR, 0.66; 95% CI, 0.57–0.76; Pheterogeneity =0.564) and the GC/CC vs. GG genotype (OR, 0.67; 95% CI, 0.58–0.77; Pheterogeneity =0.777). According to the sample size, a markedly decreased risk was identified in the subgroup with a sample size >500 (OR, 0.68; 95% CI, 0.59–0.78; Pheterogeneity =0.786 for GC vs. GG; OR, 0.68; 95% CI, 0.59–0.78; Pheterogeneity =0.738 for the GC/CC vs. GG genotype).

Bottom Line: However, the available results are inconclusive.Overall, the results of the present study demonstrated that individuals carrying the variant C allele (G/C and C/C) were associated with a significantly decreased cancer risk (OR, 0.75; 95% CI, 0.62-0.90 for GC vs.GG; OR, 0.75; 95% CI, 0.64-0.88 for GC/CC vs.

View Article: PubMed Central - PubMed

Affiliation: Department of Urology and Institute of Prostatic Diseases, The Affiliated Wuhu No. 2 People's Hospital of Wannan Medical College, Wuhu, Anhui 241000, P.R. China.

ABSTRACT
Peptidyl-prolylcis-trans isomerase NIMA-interacting 1 (encoded by the PIN1 gene) regulates the conformation of proline-directed phosphorylation sites and is important in the etiology of cancer. Since the identification of a functional polymorphism of PIN1, (-842 G>C; rs2233678), in the PIN1 promoter region, numerous studies have evaluated the association between the PIN1 promoter polymorphism (-842 G>C) and cancer risk. However, the available results are inconclusive. To derive a more precise estimation, a meta-analysis of seven previous case-control studies was performed, which included 4,524 cases exhibiting different tumor types and 4,561 control subjects. The published literature was retrieved from PubMed and EMBASE. Crude odds ratios (ORs) with 95% confidence intervals (CIs) were calculated to evaluate the strength of the association. Overall, the results of the present study demonstrated that individuals carrying the variant C allele (G/C and C/C) were associated with a significantly decreased cancer risk (OR, 0.75; 95% CI, 0.62-0.90 for GC vs. GG; OR, 0.75; 95% CI, 0.64-0.88 for GC/CC vs. GG). In further stratified analyses, a decreased cancer risk was observed in the following subgroups: Breast and lung cancer patients, Asian individuals, and in studies with a sample size >500. The results indicated that the PIN1 promoter polymorphism (-842 G>C; rs2233678) contributes to a decreased risk of cancer via attenuating the transcriptional activity.

No MeSH data available.


Related in: MedlinePlus